The stock of Assembly Biosciences Incorporated (NASDAQ:ASMB) registered a decrease of 3.82% in short interest. ASMB’s total short interest was 643,800 shares in March as published by FINRA. Its down 3.82% from 669,400 shares, reported previously. With 37,200 shares average volume, it will take short sellers 17 days to cover their ASMB’s short positions. The short interest to Assembly Biosciences Incorporated’s float is 7.2%. The stock closed at $5.04 during the last session. It is down 62.69% since August 19, 2015 and is downtrending. It has underperformed by 60.59% the S&P500.
Assembly Biosciences, Inc. is a biopharmaceutical company. The company has a market cap of $86.82 million. The Firm is engaged in the development of oral therapies for the cure of intractable infectious diseases, focusing on hepatitis B virus (HBV) and clostridium (C.) difficile-associated infections (CDAD). It currently has negative earnings. The target of Assembly’s lead program is a clinical cure for HBV, for , which it is developing a series of compounds, known as core protein allosteric modulators (CpAMs).
Assembly Biosciences Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
